INTRODUCTION
The study design for RIB 3 is presented in Figure 1. The data cutoff for this analysis was October 30, 2020.

METHODS
• RIB and OS were estimated using the Kaplan-Meier method and hazard ratios (HRs) were estimated using a stratified Cox proportional hazards model.

RESULTS
• TTR
• ORR
• PFS, (%)
• OS, (%)

Baseline Characteristics of Patients Without and With Prior CT

Figure 1. MONALEESA-3 Study Design

Figure 2. De novo vs Late Relapse Subgroups: PFS and OS (%)

Figure 3. Without vs With Prior (Neoadjuvant) Chemotherapy: PFS and OS (%)

Figure 4. Without vs With Prior Chemotherapy: PFS and OS (%; L = Early Relapse)

References
This study was sponsored by Novartis Pharmaceuticals Corporation.

Peto P1,18-21
M. Lambertini
M. Chia
S. Chia
M. Deore
A. Li
J. Wu
S. Hurvitz
J. Beck
A. Lteif
S. Haftchenary
U. Deore
A. Petrakova
C. Villanueva
S. Hurvitz
J. Beck
A. Lteif
Sina

U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 3Department of Cancer Research, Dana-Farber Cancer Institute, Boston, Massachusetts, U.S.A.; 4Medical Oncology, Charing Cross Hospital, University College London, London, U.K.; 5Medical Oncology, San Raffaele Hospital, University of Milan, Milan, Italy; 6Medical Oncology, San Filippo Neri Hospital, University of Rome, Rome, Italy; 7Medical Oncology, European Institute of Oncology, Milan, Italy; 8Medical Oncology, Institute of Oncology, University of Turin, Turin, Italy; 9Medical Oncology, University of Genoa, Genoa, Italy; 10Department of Medical Oncology, University of Turin, Turin, Italy. Contributions of industry

Figure 5. Without vs With Prior Chemotherapy: PFS and OS (%; L = Early Relapse)